Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

8.027 -0.543 (-6.34%)
Streaming Delayed Price Updated: 11:43 AM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cybin Inc. Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order ↗
Jefferies sees restrictions around non-recreational psychedelics eventually loosen up. 
Via Stocktwits
Topics Cannabis ETFs Government
News headline image
Earnings Scheduled For November 13, 2025 ↗
 
Via Benzinga
News headline image
What's Next: Cybin's Earnings Preview ↗
 
Via Benzinga
News headline image
What's going on in today's pre-market session ↗
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
3 High-Risk, High-Reward Stocks With Explosive Upside ↗
Rezolve, Aurora, and Cybin are 2025's top growth stocks in AI, driverless trucks, and psychedelics, with huge upside potential and key catalysts unfolding. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
CYBN Stock Earnings: Cybin Beats EPS for Q1 2024 ↗
CYBN stock results show that Cybin beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
CYBN Stock Earnings: Cybin Beats EPS for Q4 2023 ↗
CYBN stock results show that Cybin beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Psychedelics Policy Is Shifting In Washington: Here's What One Biotech CEO Sees Coming ↗
Federal support for psychedelics is rising fast. One biotech CEO explains what it means for clinical trials, access, and real-world therapy. 
Via Benzinga
News headline image
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors ↗
Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more. 
Via Benzinga
Topics Government
News headline image
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks. ↗
From vaccines to fluoride and beef tallow, here's where Robert F. Kennedy Jr. is making changes to health care. 
Via Investor's Business Daily
Topics Government
News headline image
MGM Resorts To Rally Around 75%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care. ↗
The Senate will vote Thursday on whether to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks. 
Via Investor's Business Daily
News headline image
RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box. ↗
RFK Jr. cleared a key hurdle Tuesday after the Senate Finance Committee voted along party lines in favor of his nomination. 
Via Investor's Business Daily
News headline image
Is Your Mind Ready to Consider Investing in Psychedelics Stocks? ↗
Don't jump in without doing some research first. 
Via The Motley Fool
News headline image
Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression ↗
Cybin starts Phase 3 trials for its depression treatment, CYB003, backed by strong Phase 2 data and a solid cash position. 
Via Benzinga
News headline image
EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program ↗
Cybin secures a U.S. patent for its CYB005 program targeting CNS disorders and prepares to launch a Phase 3 trial for CYB003 in major depressive disorder. 
Via Benzinga
Topics Intellectual Property
News headline image
Leadership Shake-Ups In Cannabis And Psychedelics: Maryland's Cannabis Chief Resigns, Costly Legal Battle In MA Drags On & More ↗
Maryland transitioned to an adult-use cannabis market a little over a year ago. Led by the state's Cannabis Administration Director, Will Tilburg, the transition resulted in the state's legal cannabis... 
Via Benzinga
Topics Cannabis
News headline image
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves ↗
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy. 
Via Benzinga
News headline image
3 Biotech Stocks That Could Make Your Summer Unforgettable ↗
If you want to do well with biotech stocks, trade the anticipation of news. Here are three stocks to consider. 
Via InvestorPlace
News headline image
Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns ↗
Psychedelics could be a game-changer in treating mental health issues, creating substantial opportunities for top psychedelic stocks. 
Via InvestorPlace
News headline image
3 Psychedelic Stocks to Buy on the Dip: Summer 2024 ↗
These are three of the best psychedelic stocks to buy on the dip for potentially lucrative future growth and returns. 
Via InvestorPlace
News headline image
Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development ↗
Explore Cybin Inc.'s FY 2024 results: $78M loss and strides in psychedelic therapy for mental health. Read now! 
Via Benzinga
News headline image
Latest Executive Cannabis Changes You Should Know About: Curaleaf, Planet 13 Elect Directors And More ↗
As the premier gathering of top entrepreneurs and investors is taking place this Monday in New Jersey, let's scroll through the latest leadership changes in the cannabis and psychedelics... 
Via Benzinga
Topics Cannabis
News headline image
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment ↗
FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision. 
Via Benzinga
News headline image
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon ↗
 
Via Benzinga
Topics Cannabis
News headline image
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More ↗
 
Via Benzinga
News headline image
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition ↗
Penny stocks are incredibly risky. However, if you can handle the heat, these ideas might be worth your while. 
Via InvestorPlace
News headline image
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More ↗
 
Via Benzinga
Topics Economy
News headline image
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement ↗
 
Via Benzinga
News headline image
3 High-Potential Penny Stocks to Turn $1000 into $1 million ↗
U.S. equities are in the midst of a steady rally, but these high-potential penny stocks are likely to trounce the major indices. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.